Aspects of «Cocktail» cytochrome P450 activity determination methods application with the view of drug treatment rationalization
Abstract
Rational pharmacotherapy is understood as intelligent drug combination and dosage adjustment for the purpose of drug adverse events development risk minimization and achievement of suitable therapeutical effect. One of the main factors affecting on drug potency is activity of biotransformation system. In this work, a review of promising "cocktail" method of biotransformation enzymes activity determination in vivo is given.
About the Authors
E. . Egorenkov
I.M. Sechenov First Moscow State Medical University; National Research Center Institute of Immunology Federal Medical Biological Agency of Russia
Russian Federation
Russian Federation
V. . Smirnov
I.M. Sechenov First Moscow State Medical University; National Research Center Institute of Immunology Federal Medical Biological Agency of Russia; FSBI «Scientific Centre for Expert Evaluation of Medical Products» of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
A. . Litvin
FSBSI «Zakusov Institute of Pharmacology»
Russian Federation
Russian Federation
G. . Kolyvanov
FSBSI «Zakusov Institute of Pharmacology»
Russian Federation
Russian Federation
G. . Ramenskaya
I.M. Sechenov First Moscow State Medical University; FSBI «Scientific Centre for Expert Evaluation of Medical Products» of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
References
1. Кукес В.Г. Метаболизм лекарственных средств: клинико-фармакологические аспекты. М.: Издетельство «Реафарм», 2004; 144.
2. Середин С.Б. Лекции по фармакогенетике. М.: МИА. 2004; 303.
3. Сычёв Д.А. Клиническая фармакогенетика. Клиническая фармакология под ред. Академика РАМН, проф. Кукеса В.Г. М.:ГЕОТАР-МЕД, 2004; 156.
4. Virginie Y. Martiny, Maria Miteva. Advances in Molecular Modeling of Human Cytochrome P450 Polymorphism // Journal of Molecular Biology. 2013; 7: 207(21).
5. Cornelis M.C., El-Sohemy A., Kabagambe E.K., Campos H. Coffee, CYP1A2 genotype, and risk of myocardial infarction // Journal of American Medical Assossiation. 2006; 295 (10): 1135(41).
6. Handbook of drug metabolism, Second Edition / Ed. by Paul G. Pearson and Larry C. Wienkers - Florida: CRC Press. 2008; 675.
7. Lewis D.F.V., Dickins M., Eddershaw P.J., Tarbit M.H., Goldfard P.S. Cytochrome P450 Substrate Specifities, Substrate structural Templates and Enzyme Active Site Geometries // Drug metabolism and drug interctions. 1999; 15: 151.
8. Zhu B., Ou-Yang D.S., Chen X.P., Huang S.L., Tan Z.R., He N., Zhou H.H. Assessment of cytochrome P450 activity by a five-drug cocktail approach // Journal of Clinical Pharmacy and Therapeutics. 2001; 70 (5): 61.
9. Yamamura Y., Koyama N., Umehara K. Comprehensive kinetic analysis and influence ofreaction components for chlorzoxazone 6-hydroxylation in human liver microsomes with CYP antibodies. // Xenobiotica. 2015; 45 (4): 353-60.
10. Peng Y., Wu H., Zhang X. et al. A comprehensive assay for nine major cytochrome P450 enzymes activities with 16 probe reactions on human liver microsomes by a single LC/MS/MS run to support reliable in vitro inhibitory drug-drug interaction evaluation. // Xenobiotica. 2015; 45 (11): 961-77
11. Christensen M., Andersson K., Dalen P., et al. The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes // Journal of Clinical Pharmacy and Therapeutics. 2003; 73: 517-528.
12. Lo M.W., Goldberg M.R., McCrea J.B. et al. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. // Clinical pharmacology and therapeutics. 1995; 58 (6): 641-9.
13. Chainuvati S., Nafziger A.N., Leeder J.S., et al. Combined phenotypic assessment of cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the ‘‘Coopers- town 5 + 1 cocktail’’ // Journal of Clinical Pharmacy and Therapeutics. 2003; 74: 437-447.
14. Yin O.Q., Lam S.S., Lo C.M., et al. Rapid determination of five probe drugs and their metabolites in human plasma and urine by liquid chromatography/tandem mass spectrometry: application to cytochrome P450 phenotyping studies // Rapid Communications in Mass Spectrometry. 2004; 18: 2921-2933.
15. Zgheib N.K., Frye R.F., Tracy T.S., et al. Validation of incorporating flurbiprofen into the Pittsburgh cocktail // Journal of Clinical Pharmacy and Therapeutics. 2006; 80: 257-263.
16. Ryu J.Y., Song I.S., Sunwoo Y.E., et al. Development of the ‘‘Inje cocktail’’ for high-throughput evaluation of five human cytochrome P450 isoforms in vivo // Journal of Clinical Pharmacy and Therapeutics. 2007; 82: 531-540.
17. Oh K.S., Park S.J., Shinde D.D., Shin J.G., Kim D.H. High-sensitivity liquid chromatography-tandem mass spectrometry for the simultaneous determination of five drugs and their cytochrome P450-specific probe metabolites in human plasma // Journal of Chromatography B, Analytical technologies in the biomedical and life sciences. 2012; 1: 56-64.
18. Ghassabian S., Chetty M., Tattam B.N., Chem M.C., Glen J., Rahme J., Stankovic Z., Ramzan I., Murray M., McLachlan A.J. A high-throughput assay using liquid chromatography-tandem mass spectrometry for simultaneous in vivo phenotyping of 5 major cytochrome p450 enzymes in patients // Therapeutic Drug Monitoring. 2009; 31 (2): 239-46.
19. Tanaka S., Uchida S., Inui N., Takeuchi K., Watanabe H., Namiki N. Simultaneous LC-MS/MS analysis of the plasma concentrations of a cocktail of 5 cytochrome P450 substrate drugs and their metabolites. Biol Pharm Bull. 2014; 37 (1): 18-25.
20. СмирновВ.В. Разработка методики определения кортизола и 6-бета-гидроксикортизола в моче с целью установления активности изофермента CYP 3A4. диссертация на соискание ученой степени кандидата фармацевтических наук М.: ГОУВПО «Московская медицинская академия». 2011.; 95.
21. Смирнов В.В., Савченко А.Ю., Раменская Г.В. Разработка и валидация методики количественного определения эндогенного кортизола и 6-β-гидроксикортизола в моче с целью определения активности изофермента CYP 3A4 // Биомедицина. 2010; 1: 4: 56 - 60.
22. Отделёнов В.А., Смирнов В.В., Дмитриев А.В., Поройков В.В., Шумянцева В.В., Красных Л.М., Сычёв Д.А., Кукес В.Г. Влияние этил-метилгидроксипиридина малата на активность CYP3A4: комплексный подход к оценке влияния на систему биотрансформации лекарственных средств // Лекарственные препараты и рациональная фармакотерапия. 2013; 3: 30-36.
23. Абдрашитов Р.Х., Гильдеева Г.Н., Г.В. Раменская Г.В., Смирнов В.В. Обзор существующих методик оценки активности CYP2D6 с применением экзогенных и эндогенных маркеров // Фармакокинетика и фармакодинамика. 2015; 1: 4-11.
24. Сычёв Д.А., Застрожин М.С., Смирнов В.В., Савченко Л.М., Брюн Е.А., Гущина Ю.Ш., Сорокин А.С., Агузаров А.Д. Ассоциация активности изофермента CYP2D6 с профилем эффективности и безопасности галоперидола у пациентов, страдающих патологическим влечением к алкоголю// Вестник РГМУ. 2015; 4: 32-36.
Review
For citations:
Egorenkov E., Smirnov V., Litvin A., Kolyvanov G., Ramenskaya G. Aspects of «Cocktail» cytochrome P450 activity determination methods application with the view of drug treatment rationalization. Pharmacokinetics and Pharmacodynamics. 2016;(1):33-37. (In Russ.)
Views:
534
Email this article 